AZD-8186

N/A

Report date: 2024/11/21 20:00:04
NME

Base Information

Drug NameAZD-8186
Drug Alias NameAZD-8186
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPhosphatidylinositol 3 kinase beta inhibitorsPhosphatidylinositol 3 kinase delta inhibitorsPhosphatidylinositol 3 kinase alpha inhibitors
TargetsPhosphatidylinositol 3 kinase betaPhosphatidylinositol 3 kinase alphaPhosphatidylinositol 3 kinase delta
Therapy Area/IndicationsMetastatic breast cancerSolid tumoursProstatic Neoplasms, Castration-Resistant +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesUnited Kingdom +[5] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesAstrazeneca Plc
China Registration ClassN/A

Develop Information

Active CompaniesNational Cancer Institute
Inactive CompaniesSeoul National University Bundang HospitalAstrazeneca Plc
Active IndicationsMetastatic breast cancerSolid tumoursProstatic Neoplasms, Castration-Resistant +[7] 
Inactive IndicationsStomach Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A